QSC Peptides · 100:100 baseline
The classic mass-building research combination: Testosterone Enanthate (full AR agonist + aromatization baseline), Nandrolone Decanoate (high anabolic:androgenic selectivity + PR activity + collagen synthesis), and Dianabol (rapid-onset oral AAS + methylestradiol estrogenicity). Three complementary pharmacological profiles targeting maximized anabolic signaling.
Shop All QSC Steroids →QSC Peptides · 100:100 baseline
QSC Peptides · Low androgenicity
QSC Peptides · C17α oral
QSC Peptides
| Compound | Receptor Targets | A:A Ratio | Aromatizes | Duration |
|---|---|---|---|---|
| Test Enanthate | AR (full agonist) | 100:100 | → E2 | Full protocol |
| Nandrolone DECA | AR + PR | 125:37 | Minimal → E1 | Full protocol |
| Dianabol 50mg | AR + ER (via MeE2) | 210:60 | → MeE2 | Weeks 1–6 (oral kickstart) |
| Clomid (PCT) | ER antagonist (hypo) | N/A | N/A | Post-protocol |
Testosterone Enanthate provides the foundational AR activation — the endogenous reference compound at 100:100. Its aromatization to E2 provides the estrogenic component (IGF-1 upregulation, bone density, CNS effects) while establishing the AR baseline against which the other compounds are studied.
Nandrolone Decanoate (DECA) adds a 19-nor AR agonist with higher anabolic selectivity (125:37) and unique progestin receptor activity. The 5α-reduction to inactive DHN means nandrolone doesn't amplify androgenicity in sensitive tissues — providing additive anabolic signaling with minimal androgenic overlap. Additionally, nandrolone increases synovial fluid production and collagen type I/III synthesis — tissue effects not produced by testosterone alone.
Dianabol as an oral compound provides rapid-onset AR activation in the first weeks of research (before injectable compounds reach full steady-state) and adds the unique pharmacology of 17α-methylestradiol — a more potent ER agonist than native E2, providing a third estrogenic research variable.